FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 283 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... February 3, 2025 ΤΙ ΕΙΝΑΙ January 18, 2019 Tables Turned June 23, 2020 FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer October 15, 2024 Load more HOT NEWS Cancer in My Community: Working to Expand Access to Clinical Trials... EMA Starts Review of Rucaparib Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... Women in science: Cancer research pioneers – part 1
